AURORA

March 8, 2019March 26, 2019

Positive Data from VX-445 Triple Combo Regimen Prompt Vertex to Seek Regulatory Approval

News

Vertex Pharmaceuticals is planning to request regulatory approval from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) during the third and fourth quarters of 2019, ... Read more

June 18, 2018June 18, 2018

Vertex Employees Donate $1M to CF and Other Communities via Matching Gift Program

cystic fibrosis, News

Vertex Pharmaceuticals employees have raised more million $1 million using the Vertex Foundation‘s matching gift program in a show of commitment to causes that include the cystic fibrosis (CF) community, a company press ... Read more

May 4, 2018May 4, 2018

Vertex Awards $400K in Scholarships to CF Patients, Family Members

cystic fibrosis, News

Vertex Pharmaceuticals recently awarded $400,000 in scholarships for people living with cystic fibrosis (CF) and their family members, as part of its second “All in for CF” scholarship program. ... Read more

May 2, 2018May 2, 2018

Vertex Announces VX-445 Phase 3 Trial Program, Positive Data on VX-561 Combo Regimen

cystic fibrosis, News

Vertex Pharmaceuticals is launching Phase 3 clinical trials to evaluate the safety and effectiveness of its investigational therapy, VX-445, in combination with VX-661 (tezacaftor) and Kalydeco (ivacaftor) for cystic fibrosis ... Read more

Pin It on Pinterest